32 assets in Hematologic Disorder

Therapeutic assets addressing Hematologic Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Hematologic Disorder	Baptist Health South Florida	P2/3	BBB (75)
Fludarabine Hematologic Disorder	Baptist Health South Florida	P2	BB (71)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription Hematologic Disorder	Vertex Pharmaceuticals Incorporated	P3	BB (70)
Busulfanum Hematologic Disorder	Baptist Health South Florida	P2	BB (69)
Lenalidomide Hematologic Disorder	Hellenic Society of Hematology	P3	BB (68)
Dexasone Hematologic Disorder	Hellenic Society of Hematology	P2	BB (67)
Tacrolimus Hematologic Disorder	University of Michigan Rogel Cancer Center	P2	BB (66)
Thiotepa Hematologic Disorder	Baptist Health South Florida	P2	BB (64)
Azacitidine Hematologic Disorder	M.D. Anderson Cancer Center	P2	B (60)
Melphalan Hematologic Disorder	Baptist Health South Florida	P2	B (60)
Pomalidomide Hematologic Disorder	Hellenic Society of Hematology	P2	B (60)
Methotrexate Hematologic Disorder	University of Michigan Rogel Cancer Center	P2	B (59)
Bortezomib Hematologic Disorder	Hellenic Society of Hematology	P2	CCC (53)
Brentuximab Vedotin Hematologic Disorder	M.D. Anderson Cancer Center	P2	CCC (53)
Isatuximab Hematologic Disorder	Hellenic Society of Hematology	P2	CCC (53)
Ranitidine Hematologic Disorder	Hellenic Society of Hematology	P2	CCC (53)
Venetoclax Hematologic Disorder	M.D. Anderson Cancer Center	P2	CCC (53)
Daratumumab Hematologic Disorder	Anaveon AG	P1/2	CCC (52)
Diphenhydramine Hematologic Disorder	Hellenic Society of Hematology	P2	CCC (51)
Belantamab Mafodotin Hematologic Disorder	Hellenic Society of Hematology	P1/2	CCC (48)
rd13-02 cell infusion Hematologic Disorder	Kai Lin Xu，MD	Early P1	CC (47)
Vorinostat Hematologic Disorder	University of Michigan Rogel Cancer Center	P1/2	CC (47)
Nirogacestat Hematologic Disorder	Hellenic Society of Hematology	P1/2	CC (45)
anv419 Hematologic Disorder	Anaveon AG	P1	CC (43)
gsk4172239d Hematologic Disorder	GlaxoSmithKline	P1	CC (43)
Kln-1010 Hematologic Disorder	Kelonia Therapeutics, Inc.	P1	CC (43)
Oricar-017 Hematologic Disorder	OriCell Therapeutics Co., Ltd.	P1	CC (43)
Levetiracetam Hematologic Disorder	Masonic Cancer Center, University of Minnesota	N/A	D (30)